What does this research mean for the field?

Patients with uncomplicated Hereditary Hemochromatosis type I have similar baseline FGF23 levels and skeletal health to healthy controls, but lack the physiological increase in cFGF23 following blood loss, likely due to persistent iron overload. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 28, 2026Journal of Endocrinological InvestigationOpen Access

Exploring the dynamics of FGF23 in patients with Hereditary Hemochromatosis type I following iron depletive treatment: a pilot study

View Full Paper

Ask AI

Bookmark

Authors

LCLuciano Colangelo STSergio Terracina CSChiara Sonato

Discussion

Member takes

Overview

Pilot study explores FGF23 levels in hereditary hemochromatosis type I, indicating persistent iron overload despite treatment.

Key Points

The aim is to explore FGF23 dynamics in patients with Hereditary Hemochromatosis type I post iron depletive treatment.
Enrolled 26 patients with genetically confirmed uncomplicated HH1 and 19 healthy controls.
Evaluated intact and C-terminal FGF23 and iron markers at baseline and seven days after treatment.
Measured bone mineral density and vertebral fracture assessment at baseline.
No significant differences in iFGF23 between HH1 and controls at both time points.
Significant increase in cFGF23 levels in controls at T7 compared to HH1.
Post treatment, serum iron, ferritin, and transferrin saturation were reduced in both groups, with HH1 remaining near the upper normal range.

Cite This Study

Colangelo et al. (2026) studied this question.

synapsesocial.com/papers/6a17dd123fad632b0f9d9cfa https://doi.org/10.1007/s40618-026-02893-5

View Full Paper

Ask AI

Bookmark

May 28, 2026Journal of Endocrinological InvestigationOpen Access

Exploring the dynamics of FGF23 in patients with Hereditary Hemochromatosis type I following iron depletive treatment: a pilot study

View Full Paper

Ask AI

Bookmark

Authors

LCLuciano Colangelo STSergio Terracina CSChiara Sonato

Discussion

Member takes

Overview

Pilot study explores FGF23 levels in hereditary hemochromatosis type I, indicating persistent iron overload despite treatment.

Key Points

The aim is to explore FGF23 dynamics in patients with Hereditary Hemochromatosis type I post iron depletive treatment.
Enrolled 26 patients with genetically confirmed uncomplicated HH1 and 19 healthy controls.
Evaluated intact and C-terminal FGF23 and iron markers at baseline and seven days after treatment.
Measured bone mineral density and vertebral fracture assessment at baseline.
No significant differences in iFGF23 between HH1 and controls at both time points.
Significant increase in cFGF23 levels in controls at T7 compared to HH1.
Post treatment, serum iron, ferritin, and transferrin saturation were reduced in both groups, with HH1 remaining near the upper normal range.

Cite This Study

Colangelo et al. (2026) studied this question.

synapsesocial.com/papers/6a17dd123fad632b0f9d9cfa https://doi.org/10.1007/s40618-026-02893-5

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark